尚荣医疗(002551) - 2025 Q2 - 季度业绩预告

Shangrong Medical 2025 Semi-Annual Performance Forecast This report provides the preliminary performance forecast for Shenzhen Shangrong Medical Co., Ltd. for the first half of 2025, indicating a significant shift from profit to loss Performance Forecast The company anticipates a shift from profit to loss in the first half of 2025, with net profit attributable to shareholders projected to be a loss of 7.0 million to 9.5 million yuan, representing a significant year-over-year decline of 135.65% to 167.73% compared to the prior year's profit of 14.0266 million yuan, while net profit after deducting non-recurring gains and losses is expected to decline even more sharply by 518.36% to 713.25% 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period (2025.01.01 - 2025.06.30) | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Loss: 7.0 million — 9.5 million yuan | Profit: 14.0266 million yuan | | Year-over-Year Change | Decrease: 135.65% — 167.73% | - | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss: 9.6594 million — 14.1594 million yuan | Profit: 2.3089 million yuan | | Year-over-Year Change | Decrease: 518.36% — 713.25% | - | | Basic Earnings Per Share | Loss: 0.006 — 0.011 yuan/share | Profit: 0.0166 yuan/share | Communication with Accounting Firm The company explicitly states that the financial data in this performance forecast has not been pre-audited by a certified public accountant, and its accuracy is subject to uncertainty - The financial data related to this performance forecast has not been pre-audited by a certified public accountant[4] Explanation of Performance Changes The company attributes the shift from profit to loss primarily to three negative factors: a significant decline in core medical professional engineering revenue, a simultaneous decrease in both volume and price for export medical consumables, and a sharp reduction in non-operating income such as government subsidies - The primary reasons for the company's loss include[5] - Medical professional engineering revenue: Revenue completed and recognized in the current reporting period decreased by 72% compared to the prior year period[5] - Export business: Sales volume and profit margins of medical consumable products further declined[5] - Non-operating income: Income from government subsidies and write-offs of receivables decreased by approximately 90% compared to the prior year period[5] Other Relevant Information The company emphasizes that this performance forecast is a preliminary estimate by the finance department, with final accurate financial data to be disclosed in the official "2025 Semi-Annual Report," and advises investors to be aware of investment risks and rely on information published by the company in designated media - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an auditing firm[6] - The company reminds investors to rely on information published in designated media such as "China Securities Journal," "Securities Times," and Juchao Information Network, and to be aware of investment risks[7]